Richter Gedeon Nyrt./Ft RICHTER
1D1W1MYTD1Y5YMAX
Capital at risk
About Richter Gedeon Nyrt.
- Ticker
- Ft RICHTER
- Sector
- Health
- Primary listing
- BUX
- Employees
- 11,155
- Headquarters
- Budapest, Hungary
- Website
- www.gedeonrichter.com
RICHTER Metrics
BasicAdvanced
Ft 2.285T
10.60
Ft 1,180
0.34
Ft 655
5.24%
Price and volume
Market cap
Ft 2.285T
Beta
0.34
52-week high
Ft 13,570
52-week low
Ft 9,380
Average daily volume
282K
Dividend rate
Ft 655
Financial strength
Current ratio
3.786
Quick ratio
2.514
Long term debt to equity
6.272
Total debt to equity
6.974
Dividend payout ratio (TTM)
41.28%
Interest coverage (TTM)
28.80%
Profitability
EBITDA (TTM)
359,846
Gross margin (TTM)
67.29%
Net profit margin (TTM)
23.34%
Operating margin (TTM)
32.96%
Effective tax rate (TTM)
18.40%
Revenue per employee (TTM)
Ft 82,930,000
Management effectiveness
Return on assets (TTM)
11.58%
Return on equity (TTM)
16.20%
Valuation
Price to earnings (TTM)
10.603
Price to revenue (TTM)
2.475
Price to book
1.68
Price to tangible book (TTM)
2.18
Price to free cash flow (TTM)
9.797
Free cash flow yield (TTM)
10.21%
Free cash flow per share (TTM)
1,277.492
Dividend yield (TTM)
5.24%
Forward dividend yield
5.24%
Growth
Revenue change (TTM)
2.40%
Earnings per share change (TTM)
-2.25%
3-year revenue growth (CAGR)
2.65%
10-year revenue growth (CAGR)
9.64%
3-year earnings per share growth (CAGR)
21.20%
10-year earnings per share growth (CAGR)
17.26%
What the Analysts think about RICHTER
Analyst ratings (Buy, Hold, Sell) for Richter Gedeon Nyrt. stock.
Analyst projections of the future price of Richter Gedeon Nyrt. stock.
Bulls say / Bears say
Richter upgraded its 2026 pharma clean EBIT guidance to double-digit growth after reporting H1 2026 pharma revenues of HUF 455.2 billion and a clean EBIT of HUF 143.5 billion on H1 revenues of HUF 461.6 billion (Stockopedia).
The European Commission granted marketing authorization for Tuyory®, Richter’s tocilizumab biosimilar, across multiple indications in the EU, Iceland, Liechtenstein and Norway, bolstering its high-margin biosimilars portfolio (Reuters).
Richter and Adalvo expanded their global co-development partnership in tirzepatide across diabetes and obesity care, anchored by shared investment, a resilient dual supply chain and focus on cost leadership, positioning for growth in the GLP-1 market (Stockopedia).
Reported Q1 2026 pharma revenues declined 1.3% YoY to HUF 217 billion due to over a 7 percentage-point FX headwind from a weaker USD and stronger HUF, offsetting underlying CER growth (MarketScreener).
GenMed segment revenues fell 8.5% YoY on a CER basis in Q1 2026 driven by lack of a flu season, portfolio streamlining, trade-related financial headwinds and distributor stock phasing in some markets (MarketScreener).
Although Richter partnered with Hetero for a semaglutide generic, regulatory filings are not expected in the EU and US until 2027, delaying any material near-term revenue contribution (Stockopedia).
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
RICHTER Financial Performance
Revenues and expenses
RICHTER Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RICHTER
AllGBPUSDEUR
Fund name | Fund size | Ft RICHTER weighting |
|---|---|---|
iShares Edge MSCI EM Minimum Volatility£EMV | £375M | 0.07% |
iShares Edge MSCI Emerging Markets Minimum Volatility$EMMV | $508M | 0.06% |
iShares MSCI EM IMI Screened€AYEM | €5.8B | 0.05% |
iShares MSCI EM ex-China€84X0 | €5B | 0.05% |
iShares MSCI EM IMI Screened£SEGM | £5B | 0.05% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by Budapest Stock Exchange.